Instrument Inactif

Autres langues TURG POIN

Actions

TPTX

US90041T1088

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Global BMI Index	19/08/22
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Biotechnology Select Industry Index	19/08/22
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P TMI Index	19/08/22
Bristol-Myers Squibb Completes Acquisition of Turning Point Therapeutics	17/08/22
Turning Point Therapeutics : Termination of a Material Definitive Agreement - Form 8-K	17/08/22
TURNING POINT THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	17/08/22
Turning Point Therapeutics, Inc. Announces Executive Changes	17/08/22
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index	17/08/22
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday	16/08/22
Bristol-Myers Squibb Company completed the acquisition of Turning Point Therapeutics, Inc. from a group of shareholders..	15/08/22
Biotech stocks pin bounce back hopes on M&A boost	12/08/22
Turning Point Therapeutics : Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC) Plan to provide detailed update for TRIDENT-1 registrational ROS1-positive NSCLC population and additional data for NTRK-positive solid tumor population, as we	09/08/22
Turning Point Therapeutics: Q2 Earnings Snapshot	08/08/22
TURNING POINT THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	08/08/22
Turning Point Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	08/08/22
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates	08/08/22
Turning Point Therapeutics, Inc. Provides Operational and Clinical Update	08/08/22
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC	27/07/22
Bristol Myers Squibb Extends Turning Point Tender Offer	19/07/22
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Biotechnology Index	18/07/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TURG POIN

Actions

TPTX

US90041T1088

Autres langues

Filtres